Clinical Trial Update: PS-341 in Treating Patients With Metastatic Malignant Melanoma [Phase 2]

View source ↗

Summary

This entry reports the completion of a Phase 2 trial evaluating PS-341 (bortezomib) in patients with recurrent or stage IV malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED